We are live on ! Find out more
MNTA

Momenta Pharmaceuticals, Inc.
MNTA

Delisted

MNTA was delisted on the 30th of September, 2020.

133 hedge funds and large institutions have $730M invested in Momenta Pharmaceuticals, Inc. in 2013 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 39 increasing their positions, 48 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

85% more call options, than puts

Call options by funds: $17.9M | Put options by funds: $9.68M

39% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 18

23% more capital invested

Capital invested by funds: $591M → $730M (+$139M)

6% more funds holding

Funds holding: 126133 (+7)

19% less repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 48

Holders
133
Holders Change
+7
Holders Change %
+5.56%
% of All Funds
3.86%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
25
Increased
39
Reduced
48
Closed
18
Calls
$17.9M
Puts
$9.68M
Net Calls
+$8.22M
Net Calls Change
+$3.47M
Name Holding Trade Value Shares
Change
Change in
Stake
JG
76
Jefferies Group
New York
$834K +$792K +47,150 New
Bank of America
77
Bank of America
North Carolina
$827K -$311K -18,503 -28%
OAM
78
Oberweis Asset Management
Illinois
$789K +$370K +22,000 +97%
Swiss National Bank
79
Swiss National Bank
Switzerland
$781K
NFA
80
Nationwide Fund Advisors
Ohio
$733K -$18.8K -1,117 -3%
New York State Teachers Retirement System (NYSTRS)
81
New York State Teachers Retirement System (NYSTRS)
New York
$678K -$31.9K -1,900 -5%
MLICM
82
Metropolitan Life Insurance Company (MetLife)
New York
$661K
ASRS
83
Arizona State Retirement System
Arizona
$647K -$73.9K -4,400 -11%
AIG
84
American International Group
New York
$632K +$3.11K +185 +0.5%
GF
85
Gerry Farber
New York
$615K
TAM
86
Tocqueville Asset Management
New York
$583K
BCM
87
Bluefin Capital Management
New York
$554K +$526K +31,332 New
DekaBank Deutsche Girozentrale
88
DekaBank Deutsche Girozentrale
Germany
$536K +$13.4K +800 +3%
PAMU
89
Pictet Asset Management (UK)
United Kingdom
$532K -$208K -12,400 -29%
CAM
90
Cormorant Asset Management
Massachusetts
$490K +$465K +27,700 New
ProShare Advisors
91
ProShare Advisors
Maryland
$476K -$374K -22,267 -45%
GCP
92
GSA Capital Partners
United Kingdom
$416K +$10.2K +606 +3%
Barclays
93
Barclays
United Kingdom
$400K -$697K -41,508 -64%
PPA
94
Parametric Portfolio Associates
Washington
$387K +$49.4K +2,940 +16%
Citigroup
95
Citigroup
New York
$387K +$132K +7,847 +56%
PA
96
Profund Advisors
Maryland
$386K +$167K +9,939 +83%
TD Asset Management
97
TD Asset Management
Ontario, Canada
$382K
LSERS
98
Louisiana State Employees Retirement System
Louisiana
$377K +$358K +21,300 New
CAM
99
Capstone Asset Management
Texas
$376K -$80.1K -4,767 -18%
PAM
100
Paradigm Asset Management
New York
$373K -$21.8K -1,300 -6%

MNTA Hedge Fund Activity: Q4 2013 in Review

133 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Momenta Pharmaceuticals, Inc. (MNTA) for Q4 2013, worth a combined $730M — up 23% from $591M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new MNTA positions and 18 closed out — a net gain of 7 holders — while 39 added to existing stakes and 48 trimmed.

The largest buyer was Visium Asset Management, adding an estimated $47.4M. The largest seller was Bridger Management, exiting entirely with an estimated $24M sold.

  • 133 institutional investors held Momenta Pharmaceuticals, Inc. (MNTA) as of Q4 2013, up from 126 in Q3 2013.
  • Funds reported $730M of Momenta Pharmaceuticals, Inc. stock for Q4 2013, up 23% quarter-over-quarter.
  • 25 funds opened new Momenta Pharmaceuticals, Inc. positions in Q4 2013 and 18 closed out, a net change of +7 holders.
  • The largest Momenta Pharmaceuticals, Inc. buyer in Q4 2013 was Visium Asset Management, an estimated $47.4M added.
  • The largest Momenta Pharmaceuticals, Inc. seller in Q4 2013 was Bridger Management, an estimated $24M sold.

Based on aggregated 13F filings for Q4 2013.